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Abstract 
We determined the prevalence of genetically determined neuromuscular diseases in adult Norwegian patients from Hordaland County. 
We identified patients using International Classification of Disease codes registered in our hospital database and reviewed patient notes to 
ensure diagnostic accuracy. To ensure maximal ascertainment, we screened both inpatient and outpatient contacts from two 5-year periods 
01.01.2005 to 31.12.2009 and 01.01.2008 to 01.01.2013, and used the second data set to define prevalence. 
Myotonic dystrophy was the commonest adult muscle disorder with a minimum prevalence of 11.84/100,000 followed by 
facioscapulohumeral muscular dystrophy at 6.42/100,000. Genetically confirmed limb-girdle muscular dystrophies had a prevalence of 
4.2/100,000 with CAPN3 mutations being the commonest followed by mutations in ANO5 and FKRP . Becker muscular dystrophy was 
rare (0.4/100,000). For the purposes of comparison, we also ascertained adults with spinal muscular atrophy (SMA) and found a prevalence 
of 4.42/100,000. 
The impact of neuromuscular disease is enormous both for the patient and for society. Progressive weakness and increasing dependency 
together with pulmonary and cardiac complications require specialised, multidisciplinary follow up. The provision of such care places 
substantial demands on health service resources. Thus, precise understanding of both type of neuromuscular disease and numbers of patients 
is essential in order to manage individuals appropriately and plan future health service needs. 
© 2020 The Author(s). Published by Elsevier B.V. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 























Diseases affecting muscle, whether primary or secondary
.g. to disturbance elsewhere in the motor unit, lead to
eakness and motor disability. The majority of primary
uscle disorders are progressive and associated with
ncreasing functional decline and dependency. Moreover, the
mpact of muscle disease is not limited to the patient, but
xtends to the patient’s family, other caregivers and to society.∗ Corresponding author at: Department of Neurology, Haukeland University 
ospital, 5021 Bergen, Norway. 
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 http://creativecommons.org/licenses/by/4.0/ ) Currently, few cures are available and symptomatic
reatments, particularly those directed at maintaining function
nd preventing complications such as contractures and
entilatory insufficiency are the mainstays of management. 
are of patients with muscle disease requires interdisciplinary
ooperation usually involving neurologists, physiotherapists, 
ccupational therapists, lung and orthopaedic surgeons [1] . 
Improved understanding of the consequences of 
euromuscular insufficiency, including for example the 
mpact on nocturnal ventilation, has led to improved quality
f life and survival [2] . New treatment paradigms offer
ven greater potential and, while the new genetic therapies
ay not cure, there is now good reason to hope they will
xtend and improve quality of life even further [3] . In ordercess article under the CC BY license. 















































Numbers of patients with muscular dystrophy and related conditions. 
Ascertained Minus dead per 100,000 
FSHD 34 32 6.42 
LGMD 29 28 5.62 
Becker 2 2 0.40 
DMD 11 10 2.01 
Other 13 12 2.40 
Total 89 84 16.85 
Figures for the major categories of muscle disease (dystrophies and 
myopathies) derived from the second cohort with reference to the first cohort 
of patients. The category of LGMD includes all patients both with final 
genetic diagnosis and without. Only patients alive during the second period 
were used to generate prevalence (minus dead column). 
Becker, Becker muscular dystrophy; DMD, Duchenne muscular dystrophy; 
FSHD, fasioscapulohumeral muscular dystrophy; LGMD, Limb Girdle 
muscular dystrophy. Other, Muscle-eye-brain disease; oculopharyngeal 
muscular dystrophy; scapuloperoneal syndromes; manifesting adult females 
with X-linked myotubular myopathy; oculopharyngeal distal phenotype. 
Table 2 
Numbers of patients with myotonia. 
Ascertained Minus Dead Per 100,000 
DM1 58 54 10.84 
DM2 6 5 1.00 
Myotonia Congenita 14 14 2.81 
Total 78 73 14.65 





























o  understand the implications of the new treatment modalities
for both health care provision and society, and thus plan
health service provision appropriately, it is necessary to have
comprehensive data concerning the number of patients and
type of muscle disease. To this end, we performed the first
epidemiological study of inherited muscle disease in the
Norwegian population. 
2. Materials and methods 
The study was performed at Haukeland University
Hospital. This is the only neurological centre serving
Hordaland County. Typically, all adult patients with muscle
disease are referred to this hospital, and patients with
childhood onset disorders are referred to our centre when
reaching adulthood. We used the International Classification
of Disease version 10 (ICD-10) codes to ascertain patients
through our hospital database, which records all in-patient
and outpatient contacts linked to the patient’s unique identity
number. Our primary focus was inherited muscle disease, but
we include data on spinal muscular atrophy for comparative
purposes. The following ICD-10 codes were used: G120,
121, 122; G710, 711, 712, 713. To ensure any patients
later re-classified were not missed, we also reviewed all
those with the following: G718–720, G723–24, G728–
729, G736, M30–332, M339, M600, M608–609, M628–
629 looking for final diagnosis, and performed the search
over two overlapping periods, 01.01.2005 to 31.12.2009 and
01.01.2008 to 01.01.2013. Only patients who were alive in the
second period were included. Further, only patients who had
their clinical diagnosis confirmed by one of the neurologists
in our specialised muscle clinic (PSS, LAB) were included.
Patients with no genetic mutation and an unclear phenotype
or inconclusive biopsy findings were excluded. Some patients
classified clinically as LGMD or a scapuloperoneal syndrome
had their genetic diagnosis clarified after completion of our
survey; where this was the case, we have simply included the
patient in the relevant disease category. 
We used postal address code to identify patients living
in Hordaland County for which the whole population
on 01.01.13 was 498,135 (Norwegian Central Bureau of
Statistics; SSB). We recorded the following demographic and
diagnostic data: age, gender, address; primary diagnosis (ICD-
10) and any other additional diagnoses; method and date
of diagnosis. The study was approved by the hospital as a
Quality Assurance project (2010/3283). 
3. Results 
We used the whole population number of 498,135 as
the denominator for calculating point prevalence on the
01.01.2013. Patients who had died during the second study
period were not included in the point prevalence. 
We identified 89 patients with an established or probable
genetically determined muscular dystrophy/myopathy of
whom 5 had died during the second 5-year period of
study ( Table 1 ). The major categories included FSHD,GMD, dystrophin-linked disease and an assortment of other
onditions including oculopharyngeal muscular dystrophy
OPMD), Laings myopathy and scapuloperoneal syndromes.
ne patient with biopsy proven Nemaline myopathy and one
ith an oculopharyngeal distal myopathy were not genetically
larified, but based on the presence of other affected family
embers were included as genetically determined disorders
 Table 1 ). The largest single disease category was FSHD with
4 patients of whom two died during the ascertainment period
iving a point prevalence on 01.01.13 of 6.42/100,000. The
ajority of these patients were FSHD type 1, however, two
rothers were later found (after 2013) to have mutations in
he SMCHD1 gene and were classified as FSHD type 2. 
The prevalence of LGMD was 5.62/100,000; excluding
hose without a clear genetic diagnosis lowered the figure
o 4.22/100,000. Ten of 11 patients with Duchenne muscular
ystrophy (DMD) were alive at the point of analysis giving
 prevalence of 2.01/100,000. The prevalence of Becker
uscular dystrophy was considerably less at 0.4/100,000. 
Seventy-eight patients had a dystrophic or non-dystrophic
yotonic disorder (G71.1) ( Table 2 ) and the majority of
hese had myotonic dystrophy type 1 (DM1). Interestingly,
e found 14 patients with myotonia congenita (MC) giving
 point prevalence of 2.81/100,000. All of these had
onfirmed CLCN1 mutations, and the majority showed
ecessive inheritance. 
We also ascertained adult patients with genetically
onfirmed (5q associated) spinal muscular atrophy attending
ur muscle clinic and found 23 of whom 22 were alive on
S.A. Husebye, C.B. Rebne and A.-E. Stokland et al. / Neuromuscular Disorders 30 (2020) 181–185 183 
Table 3 
Shows the overall impact of neuromuscular disease. 
Disease group Total ascertained Alive Per 100,000 
Muscle diseases 89 84 16.86 
Myotonic disorders 78 73 14.65 
McArdles 6 4 0.80 
Hypokalemic Periodic Paralysis 5 5 1.00 
SMA (over 18) 23 22 4.42 
Total 203 190 37.73 
We have grouped the major categories together to provide insight into the 














































Fig. 1. Map of Norway showing the county of Hordaland in red. (From 































1.01.13. Six patients with genetically confirmed McArdles
nd five with hypokalaemic periodic paralysis were also
dentified and while most of the latter were not genetically
onfirmed, they are included here to highlight the spectrum
f diseases found. 
The commonest limb girdle muscular dystrophies in our
opulation were caused by Calpain (LGMDD4/LGMD2A/ 
GMDR1) and anoctamin 5 (LGMD2L/LGMDR12) 
utations ( Table 3 ). These would have been equally prevalent
xcept that one patient with LGMD2L died during the study
eriod. In all but two cases of CAPN3 mutation, we found
 heterozygous a 21-bp, in-frame deletion (c.643_663del21). 
ne other patient was compound heterozygous for a known
hange and a probable pathogenic variant. The majority of
GMD2L patients carried the founder ANO5 mutation c.191
up A, while three were compound heterozygotes with other
ombinations. LGMD 2I was not as common in our cohort
s either 2A or 2L; the commonest FKRP mutation was the
.826C > A. 
The largest number of patients in whom we had no
enetic diagnosis had a limb-girdle phenotype. With the
dvent of new sequencing techniques, many of these have
een clarified since this study period ended including one with
GMD2B and homozygous dysferlin mutation and one who
ad COL6A1 mutations and who has Bethlem myopathy and
hus not LGMD. Five patients, who clinically had proximal
eakness and biopsy findings consistent with a LGMD,
emain genetically undiagnosed. Interestingly, no cases of
ompe disease were identified despite sequencing this gene in
ll the cases with a genetically undefined LGMD phenotype.
hile this may be due to this study’s population size, we are
ware that few cases of Pompe disease have been identified
n the country as a whole. 
We excluded patients with no genetic mutation and an
nclear phenotype or inconclusive biopsy findings. While
ome of these may later turn out to have LGMD or other
ype of genetically determined muscle disease, we chose not
o include them in this study. Patients classified as “other”
ncluded: two brothers with Muscle-eye-brain disease and
utation in POMT1 , two with oculopharyngeal muscular
ystrophy and PABNA1 mutations, four with scapuloperoneal
yndromes of whom 2 had mutation in TRPV4 (father
nd daughter) and two had an FHL1 mutation (mother
nd son); and two adult females with mutations in MTM1nd manifesting X-linked myotubular myopathy. One patient
ith an oculopharyngeal distal phenotype has also not been
enetically characterised. 
. Discussion 
Hordaland County ( Fig. 1 ) is the third most populated
ounty in Norway and contains one major city (Bergen),
everal smaller towns and a substantial rural population.
he Department of Neurology, Haukeland University Hospital
s the only neurological centre serving this population.
hile this means that ascertainment is good for muscular
ystrophies, i.e. disorders that give progressive weakness,
ilder variants of myotonic dystrophy, myotonia congenita
nd FSHD, may have gone unrecognised. Our figures
or these conditions are, therefore, estimates of minimum
revalence. This study focussed only on adult patients
nvestigated and followed up in a specialised multidisciplinary
utpatient clinic that caters for all types of neuromuscular
isease including spinal muscular atrophy (SMA), but not
LS, myasthenia or peripheral neuropathies such as CMT. 
We included patients registered with DMD. While
scertainment of these patients is likely to be incomplete,
e felt this data was important to inform us about potential
umbers attending our adult clinic and, since DMD has
een studied more than most other muscle diseases, for
omparative purposes [4] . The number of cases with Becker
uscular dystrophy (BMD) appeared lower than we might
ave expected based on studies performed in Northern
ngland, where the estimate was 7.29/100,000 [5] . Our figure
f 0.4/100,000 is closer to that found in a study from Sweden
hat showed 1.6/100,000 [6] . 








































































































We found an overall prevalence for LGMD of 5.62/100,000
and for those with a genetic diagnosis, the figure
was 4.2/100,000. In a study performed in 2009 in
Northern England, the estimated prevalence of LGMD was
2.27/100,000 [5] . While it is possible that there are major
discrepancies between Northern European countries, it is also
possible that the improvement of genetic testing has made it
easier for us to classify these patients. 
The spectrum of limb girdle muscular dystrophies is
different to that we expected based on previous studies. In
an earlier Norwegian study, the prevalence of LGMD2I was
1.85/100,000 [7] . We, therefore, expected this to be the most
prevalent type, but this was not the case. The prevalence
of LGMD2I was 0.8/100,000 while for LGMD2L it was
1.61/100,000. Patients with CAPN3 mutations can have either
dominant or recessive disease and in our population, the
majority (7 of 9) had the recently described, dominantly
inherited 21-bp, in-frame deletion (c.643_663del21) [8] .
Only two had recessive disease and both were compound
heterozygotes. Patients with the dominantly inherited form
of calpainopathy had a typical LGMD phenotype albeit with
predominant involvement of gait, and they tended to have a
milder and later onset disorder. 
Similar to other countries, FSHD is the second most
common muscular dystrophy in our population. Compared to
Holland, where they registered a figure of 12/100,000 [9] ,
the prevalence in our population was lower at 6.42/100,000,
but almost double that found in N.E England where the
prevalence was estimated to be 3.95/100,000 [5] . FSHD
manifests a wide range of severities from very severe, early
onset associated with mental retardation and eye involvement
(2 patients in our population), to patients with minor scapula
winging who may never come to medical attention. It is
likely, therefore, that ascertainment of this disorder is an
underestimate. Two of our patients (brothers) had FSHD type
2 and this diagnosis was also made during the second period
of assessment. 
Myotonic dystrophy is the most common muscle disease
in the adult population and our study confirms this. While
our figure of 11.84/100,000 reflects minimum prevalence
only, we have more than 60 adult patients with myotonic
dystrophy in a population of just under 500,000. DM1 and
DM2 are disorders that combine multisystem involvement and
progressive disability with cognitive disabilities that mean that
patients often neglect their disease. Even those with mild
disease can experience major problems engaging in normal
everyday activities. Potentially serious respiratory and cardiac
complications that can affect even mildly affected, demand
vigilance and regular follow up and show how important it is
to perform prevalence studies such as these. 
The number of patients with myotonia congenita
(2.8/100,000) appears high [10] , but is in fact lower than
that found in another area of Norway. A study performed
in Northern Norway [11] found a prevalence of 9/100,000
similar to that found in Northern Finland [12] . The Norwegian
population may be atypical due to a potential bottleneck
caused by the decimation caused by the plague in the 14entury, and by its geography that constrained population
ovement prior to the last century. While this is likely to
ffect recessive diseases more than dominantly inherited ones,
ith the exception perhaps of myotonia congenita, our figures
re not markedly different to those produced elsewhere. 
To get an idea of the overall demand for neurological
ervice provision, we grouped the diseases together: adding
he number with an established or probable genetically
etermined muscular dystrophy with myotonic dystrophy gave
 prevalence figure 31.51/100,000. If we add to this those
ith SMA, the figure rises to 35.93/100,000. Adding those
ith hypokalemic periodic paralysis and McArdles brings the
gure to 37.73/100,000. Including all those who died during
he period, but who were at some point reviewed in clinic,
he figure rises to 40.35. Treatment of these patients currently
nvolves a combination of local services together with a wide
ange of hospital specialists including doctors from several
pecialities, physiotherapists, occupational therapists etc. The
omplexity of this is also changing with the introduction
f new and, if the new treatment for SMA is any guide,
ery expensive medicines. While SMA treatment is currently
eserved for those under 18 in Norway, the number of patients
n our study that have survived into adulthood, provides an
ndication of the numbers we will be treating. 
. Conclusions 
In this study of the prevalence of inherited neuromuscular
iseases in Norway, we show that the number and range
f neuromuscular disease is comparable to other European
entres although interesting differences such as the prevalence
f Becker and myotonia congenita exist. The accumulated
inimum prevalence of muscular dystrophies, myotonic
isorders and SMA of 1:2600 demonstrates that these
isorders will continue to have major impact on heath service
rovision for the foreseeable future. 
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